Sarcopenia
Conditions
Brief summary
The purpose of this study is to determine how omega-3 fatty acids influence muscle protein metabolism and mitochondrial physiology in the context of human aging.
Interventions
DRUGOmega-3 fatty acids
Sponsors
Mayo Clinic
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 18-35 or 65-85 years
Exclusion criteria
1. Current use of omega-3 nutritional supplements 2. Fasting plasma glucose ≥126 mg/dL 3. Active coronary artery disease 4. Participation in structured exercise (\>3 times per week for 30 minutes or longer) 5. Smoking 6. Medications known to affect muscle metabolism (e.g., beta blockers, corticosteroids, tricyclic-antidepressants, benzodiazepines, opiates, barbiturates, anticoagulants) 7. Renal failure (serum creatinine \> 1.5mg/dl) 8. Chronic active liver disease (Bilirubin \> 17mmol/L, AST\>144IU/L, or ALT\>165IU/L) 9. Anti-coagulant therapy (warfarin/heparin) 10. INR \>3 11. Use of systemic glucocorticoids 12. Chronic use of NSAIDS or aspirin 13. Pregnancy or breastfeeding 14. Alcohol consumption greater than 2 glasses/day 15. Hypothyroidism 16. Fish or shellfish allergy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Muscle protein synthesis | Baseline and following 4 months intervention | Skeletal muscle protein synthesis will be measured from the rate of incorporation of infused amino acids measured by mass spectrometry. |
| Change in Muscle mitochondrial function | Baseline and following 4 months intervention | Mitochondrial function will be measured in isolated mitochondria by high-resolution respirometry. |
Countries
United States
Outcome results
None listed